BioSpace News Archive

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two panels discussing antifungal and COVID-19 therapies at the upcoming Infectious Disease Virtual Conference presented by Maxim Group. Presentation Information: Panel: “Anti

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the first quarter ended March 31, 2020 via a press release on May 12, 2020. About Vir Biotechnology Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edg

-- Conference Call Scheduled for 11:00 a.m. ET -- -- Key U.S. Regulatory Milestones Remain on Track, Including May 25, 2020

Phase 1 Dose-Escalation Trial in Therapy-Refractory Solid Tumors to Begin in 2020

INO-4800 Phase 2/3 U.S. clinical trial being prepared to start this summer Parallel preclinical challenge studies ongoing

NeuroOne Medical Technologies Corporation, a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces the appointment of Vanessa Tolosa to its Scientific Advisory Board.

Artio Medical, Inc. (Artio), a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced the appointment of entrepreneur and businessman Nathaniel Hagedorn to its Board of Directors

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2020. As of March 31, 2020, Odonate had $153.1 million in cash, compared to $180.5 million as of December 31, 2019. Net cash used in operating activities for the thre

LabShares Newton, a shared office and laboratory incubator for emerging biotechnology and life science companies, today announced that it has selected three startup companies developing COVID-19 diagnostics to receive free lab space

Wearables have become another weapon to track, monitor, and fight the progression of COVID-19 and its symptoms worldwide.